Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADF TSE:CCT NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADFAldel Financial$11.36+2.5%$14.48$9.61▼$11.19$169.81MN/A94,502 shs522,397 shsCCTCatamaranC$0.00C$0.00▼C$0.00N/AN/A775,784 shsN/AMRKMerck & Co., Inc.$122.09+5.4%$115.79$75.40▼$125.14$301.63B0.1810.82 million shs6.76 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADFAldel Financial0.00%0.00%0.00%-3.15%+19.20%MRKMerck & Co., Inc.+2.52%+2.34%+2.87%-5.07%+50.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADFAldel Financial$11.36+2.5%$14.48$9.61▼$11.19$169.81MN/A94,502 shs522,397 shsCCTCatamaranC$0.00C$0.00▼C$0.00N/AN/A775,784 shsN/AMRKMerck & Co., Inc.$122.09+5.4%$115.79$75.40▼$125.14$301.63B0.1810.82 million shs6.76 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADFAldel Financial0.00%0.00%0.00%-3.15%+19.20%MRKMerck & Co., Inc.+2.52%+2.34%+2.87%-5.07%+50.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADFAldel Financial 0.00N/AN/AN/ACCTCatamaran 0.00N/AN/AN/AMRKMerck & Co., Inc. 2.68Moderate Buy$128.184.98% UpsideCurrent Analyst Ratings BreakdownLatest ADF, MRK, G4M, and CCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$125.005/1/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/1/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$150.00 ➝ $145.004/13/2026MRKMerck & Co., Inc. UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $145.004/6/2026MRKMerck & Co., Inc. JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$125.00 ➝ $135.003/30/2026MRKMerck & Co., Inc. Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$142.003/20/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$120.00 ➝ $125.003/17/2026MRKMerck & Co., Inc. Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/12/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$135.00 ➝ $150.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADFAldel FinancialN/AN/AN/AN/A($0.93) per shareN/ACCTCatamaranN/AN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$65.01B4.64$12.34 per share9.89$18.60 per share6.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADFAldel FinancialN/AN/AN/AN/AN/AN/AN/AN/AN/ACCTCatamaranN/AN/AN/AN/AN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$18.25B$3.5534.4012.482.5413.59%27.55%10.73%8/4/2026 (Estimated)Latest ADF, MRK, G4M, and CCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADFAldel FinancialN/AN/AN/AN/AN/ACCTCatamaranN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.402.78%+5.75%95.77%14 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADFAldel FinancialN/A14.1114.11CCTCatamaranN/AN/AN/AMRKMerck & Co., Inc.1.021.301.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADFAldel Financial18.53%CCTCatamaranN/AMRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipADFAldel FinancialN/ACCTCatamaranN/AMRKMerck & Co., Inc.0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADFAldel Financial214.95 millionN/ANot OptionableCCTCatamaranN/AN/AN/ANot OptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableADF, MRK, G4M, and CCT HeadlinesRecent News About These CompaniesMerck Stock Gains On Positive EU Opinion For Cancer Therapy26 minutes ago | finance.yahoo.comAbbVie, Merck, Astra among winners of EU drug recommendations this week26 minutes ago | seekingalpha.comSummit downgraded at HC Wainwright after Merck data for sac-TMT26 minutes ago | msn.comMerck and Kelun's lung cancer combo bests Keytruda in late-stage trial26 minutes ago | seekingalpha.comStock Market Today: Dow Holds Gain Despite Consumer Data Surprise; Dell Soars On This News (Live Coverage)26 minutes ago | finance.yahoo.comWill Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?37 minutes ago | zacks.comPharma Stock Pops On European Seal of Approval1 hour ago | schaeffersresearch.comMerck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.2 hours ago | barrons.comMerck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer2 hours ago | investors.comAmylyx Stock: Why the Full Pipeline Story Matters (MRK)...4 hours ago | marketbeat.comMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer4 hours ago | businesswire.comKeudell Morrison Wealth Management Invests $1.33 Million in Merck & Co., Inc. $MRKMay 22 at 7:13 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Bought by Pinnbrook Capital Management LPMay 22 at 6:34 AM | marketbeat.comAxxcess Wealth Management LLC Buys 263,633 Shares of Merck & Co., Inc. $MRKMay 22 at 3:21 AM | marketbeat.com2 Reasons to Watch MRK and 1 to Stay CautiousMay 22 at 1:22 AM | finance.yahoo.comIngenia Therapeutics, a Clinical-Stage Biotechnology Company, Has Received Approval for an Initial Public Offering on the Korea Exchange (KRX)May 21 at 8:21 PM | finance.yahoo.comKelun, Merck's lung cancer combo improves survival in late-stage China trialMay 21 at 5:06 PM | reuters.comModerna, Merck cancer combo cuts melanoma spread risk at five yearsMay 21 at 5:03 PM | reuters.comEli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?May 21 at 11:16 AM | zacks.comTop Dividend Stocks To Consider In May 2026May 21 at 9:20 AM | finance.yahoo.comHow Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value OutlookMay 21 at 9:20 AM | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADF, MRK, G4M, and CCT Company DescriptionsAldel Financial NYSE:ADFAldel Financial Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Itasca, Illinois.Catamaran TSE:CCTCatamaran Corporation (Catamaran) is a provider of pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefit management industry. The Company operates in two segments: PBM and HCIT. The Company offers PBM services, which are marketed under the Catamaran PBM brand, and is engaged in owning and operating a network of mail and specialty pharmacies. In addition, the Company is a national provider of drug benefits to its customers under the federal government's Medicare Part D program. The Company's HCIT product offerings include a range of software products for managing prescription drug programs and for drug prescribing and dispensing. The Company's customers include organizations in the pharmaceutical supply chain, such as pharmacy benefit managers, managed care organizations, self-insured employer groups, unions, third-party healthcare plan administrators, and state and federal government entities.Merck & Co., Inc. NYSE:MRK$122.09 +6.21 (+5.36%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Lowe's Finds Support at $215 After Q1 Earnings Sell-Off Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
